Global Cognitive Impairment Associated with Schizophrenia Market Size To Exceed USD 9.54 Billion by 2035 | CAGR of 5.19% : Market Study Report

• As per Spherical Insights & Consulting, The Global Cognitive Impairment Associated with Schizophrenia Market Size is Expected to Grow from USD 5.47 Billion in 2024 to USD 9.54 Billion by 2035, at a CAGR of 5.19% during the forecast period 2025-2035, going to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Cognitive Impairment Associated with Schizophrenia Market Companies such as Eli Lilly and Company, Johnson & Johnson, Roche Holding AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., GlaxoSmithKline plc, Merck & Co., Inc., Alkermes plc, Biogen Inc., AstraZeneca plc., and Others.

 

 

Cognitive Impairment Associated with Schizophrenia Treatment Market: Understanding and Treatment Algorithm:

Cognitive Impairment Associated with Schizophrenia (CIAS) Market Size refers to persistent deficits in memory, attention, processing speed, and executive function experienced by individuals with schizophrenia. These impairments affect daily functioning, social interaction, and treatment outcomes. CIAS is not fully addressed by standard antipsychotics, requiring targeted therapies for improved cognitive and functional recovery.

 

Cognitive Impairment Associated with Schizophrenia Diagnosis:

Diagnosis involves clinical assessments, cognitive testing, and patient history evaluation. Tools like the MATRICS Consensus Cognitive Battery (MCCB) are commonly used to measure specific cognitive domains. Diagnosis focuses on identifying deficits beyond psychotic symptoms to guide appropriate treatment and support functional rehabilitation.

 

Cognitive Impairment Associated with Schizophrenia Treatment:

Treatment focuses on improving cognitive functions through pharmacological and non-pharmacological approaches. Cognitive enhancers, NMDA receptor modulators, and novel agents are under development, while psychosocial interventions like cognitive remediation therapy are also effective. Current antipsychotics provide limited benefit, highlighting the need for targeted cognitive therapies.

 

Principal Insights

This section offers a global overview of the cognitive impairment associated with schizophrenia epidemiology in major markets worldwide.

 

Country-Wise Cognitive Impairment Associated with Schizophrenia Multiforme Epidemiology

• The epidemiology segment provides Cognitive Impairment Associated with Schizophrenia prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Cognitive Impairment Associated with Schizophrenia: Recent Developments:

• In October 2024, Johnson & Johnson announced the presentation of 23 abstracts at the U.S. Psychiatric and Mental Health Congress, showcasing new real-world and clinical data from its neuropsychiatry portfolio. The presentations included findings on SPRAVATO® nasal spray and long-acting injectables for schizophrenia, emphasizing treatment efficacy and the burden of major depressive disorder.

 

Cognitive Impairment Associated with Schizophrenia Marketed Drugs:

• Zyprexa (olanzapine): Eli Lilly and Company

Zyprexa is a second-generation antipsychotic used to treat schizophrenia and bipolar disorder. While primarily for psychotic symptoms, it has demonstrated modest improvements in cognitive domains like verbal memory and executive function, making it relevant in addressing cognitive deficits associated with schizophrenia.

 

• Risperdal (risperidone): Johnson & Johnson

Risperdal is an atypical antipsychotic approved for schizophrenia and related conditions. It shows partial efficacy in managing cognitive symptoms, especially attention and working memory, though it is not specifically indicated for CIAS. It remains widely used in combination therapy settings.

 

• Latuda (lurasidone): Sumitomo Pharma

Latuda is approved for schizophrenia and bipolar depression. It is known for having a favorable cognitive profile among antipsychotics, showing benefits in attention, verbal learning, and working memory, making it a preferred option in cases with significant cognitive involvement.

 

Cognitive Impairment Associated with Schizophrenia: Emerging Therapies

• Iclepertin: It is a glycine transporter 1 (GlyT1) inhibitor developed to enhance NMDA receptor function and improve cognition in schizophrenia. Despite progressing to Phase III trials, recent studies did not meet efficacy endpoints. It was designed to address cognitive symptoms without worsening psychosis or causing sedation.

 

• RL 007: It is a novel compound modulating cholinergic, GABA B, and NMDA pathways. It is in Phase II trials for CIAS and aims to enhance synaptic plasticity and cognitive processing. Early data suggest positive effects on working memory and attention with a well-tolerated safety profile.

 

• Luvadaxistat: It is a D amino acid oxidase inhibitor intended to elevate D serine levels, thereby enhancing NMDA receptor function. Developed for CIAS, its Phase II ERUDITE study showed no significant improvement in cognition, though further exploration is ongoing for optimal dose and patient response.

 

• ALTO 101: It is a phosphodiesterase 4 (PDE4) inhibitor being evaluated for cognitive enhancement in schizophrenia. It has completed Phase I trials with a transdermal patch formulation that may improve tolerability. The drug aims to improve attention and executive function by modulating intracellular signaling.

 

Cognitive Impairment Associated with Schizophrenia Market Outlook

• The Cognitive Impairment Associated with Schizophrenia (CIAS) market includes therapies, diagnostics, and supportive treatments targeting cognitive deficits in schizophrenia patients. It focuses on improving memory, attention, and executive functions to enhance patient quality of life and daily functioning beyond controlling psychotic symptoms.

 

• Rising prevalence of schizophrenia, growing awareness of cognitive symptoms, increasing adoption of cognitive enhancers, and advances in neuropsychiatric research drive market growth. Additionally, expanding healthcare infrastructure and favourable reimbursement policies support higher treatment rates globally.

 

• Emerging targeted therapies, growing geriatric and diagnosed patient populations, expansion in developing regions, and increased investments in CNS drug development present significant growth opportunities. Novel drug delivery systems and combination therapies further enhance treatment accessibility and adherence.

 

• Governments promote mental health awareness, fund neuropsychiatric research, and support rare disease and CNS disorder programs. Policies improving access to treatment and encouraging innovation through grants and fast-track approvals strengthen the CIAS treatment landscape globally.

 

• Limited efficacy of current treatments and high drug development costs hinder rapid market expansion.

 

• The CIAS market is projected to grow steadily due to rising demand for effective cognitive therapies and continuous innovation addressing unmet clinical needs.

 

Cognitive Impairment Associated with Schizophrenia Market Segmentation

By Drug Class:

• Cognitive Enhancers
• NMDA Receptor Antagonists
• Antipsychotic Medications

 

 

Cognitive Enhancers hold the largest market share because they directly target cognitive deficits in schizophrenia, addressing memory, attention, and executive function impairments. Their increasing clinical adoption, favorable efficacy profiles, and growing research support their role as essential adjunct therapies, driving demand over NMDA receptor antagonists and traditional antipsychotics.

 

By Indication:

• Schizophrenia with Cognitive Impairment
• Bipolar Disorder with Cognitive Impairment
• Major Depressive Disorder with Cognitive Impairment

 

 

Schizophrenia With Cognitive Impairment dominates the indication segment due to the high prevalence of cognitive dysfunction in these patients. The significant impact on daily functioning and quality of life increases the need for targeted treatments, leading to greater market focus and investment in therapies addressing this primary group.

 

Regional Segment Analysis of the Cognitive Impairment Associated with Schizophrenia Market

North America holds the largest share in the cognitive impairment associated with schizophrenia market due to advanced healthcare infrastructure, higher awareness of mental health conditions, and access to innovative therapies. The presence of major pharmaceutical companies, increased investment in neuropsychiatric research, and supportive reimbursement policies further strengthen the region's dominance. Additionally, robust clinical trial activity and early adoption of novel cognitive-enhancing drugs contribute to sustained market leadership.

 

Asia-Pacific is the fastest-growing region in this market, driven by the rising prevalence of psychiatric disorders, growing mental health awareness, and expanding access to healthcare services. Governments across countries like China, India, and Japan are increasingly investing in neurodegenerative disease research and treatment infrastructure. The growing acceptance of cognitive therapies, along with rising disposable income and urbanization, is accelerating market expansion across the region.

 

Cognitive Impairment Associated with Schizophrenia Market Key Companies

• Eli Lilly and Company
• Johnson & Johnson
• Roche Holding AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• H. Lundbeck A/S
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Alkermes plc
• Biogen Inc.
• AstraZeneca plc.
• Others

 

Cognitive Impairment Associated with Schizophrenia Therapeutics Market Report Scope

• The Cognitive Impairment Associated with Schizophrenia therapeutics market size report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Cognitive Impairment Associated with Schizophrenia’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Cognitive Impairment Associated with Schizophrenia therapies is provided, including an evaluation of new treatments expected to influence the current Cognitive Impairment Associated with Schizophrenia treatment market landscape.
• The report includes a detailed review of the Cognitive Impairment Associated with Schizophrenia therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Cognitive Impairment Associated with Schizophrenia Market Forecasting report offers valuable insights into trends shaping the global Cognitive Impairment Associated with Schizophrenia market, helping to develop effective business strategies.

 

Cognitive Impairment Associated with Schizophrenia Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Cognitive Impairment Associated with Schizophrenia Therapeutic Approaches in Cognitive Impairment Associated with Schizophrenia
• Review Of Drugs in Development for Cognitive Impairment Associated with Schizophrenia
• Market, Growth, and Trends in Cognitive Impairment Associated with Schizophrenia
• Market Opportunities in Cognitive Impairment Associated with Schizophrenia Treatment
• Effects Of Future Therapies on Cognitive Impairment Associated with Schizophrenia Treatment.

 

Cognitive Impairment Associated with Schizophrenia Treatment Market Report Key Strengths

• 15 Years Cognitive Impairment Associated with Schizophrenia Market Forecast
• Global Coverage
• Cognitive Impairment Associated with Schizophrenia Epidemiology Segmentation
• Key Cross Competition

 

Cognitive Impairment Associated with Schizophrenia Treatment Market Report Assessment

• Present Practices in the Cognitive Impairment Associated with Schizophrenia Treatment Market
• Review of Investigational Cognitive Impairment Associated with Schizophrenia Drugs
• Attractiveness of the Cognitive Impairment Associated with Schizophrenia Drug Market
• Cognitive Impairment Associated with Schizophrenia Market Drivers
• Cognitive Impairment Associated with Schizophrenia Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the cognitive impairment associated with schizophrenia market based on the below-mentioned segments:

 

Global Cognitive Impairment Associated with Schizophrenia Market, By Drug Class

• Cognitive Enhancers
• NMDA Receptor Antagonists
• Antipsychotic Medications

 

Global Cognitive Impairment Associated with Schizophrenia Market, By Indication

• Schizophrenia with Cognitive Impairment
• Bipolar Disorder with Cognitive Impairment
• Major Depressive Disorder with Cognitive Impairment

 

Global Cognitive Impairment Associated with Schizophrenia Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa